ClinicalTrials.gg
RecruitingNCT05163600CaRe-BFRUpdated Jul 7, 2026

The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR)

An interventional study of BFR-CYC 50% peak / 50% AOP (exhaustive) and BFR-CYC 3x2min in COPD, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich — 1 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University of Zurich.

Planned enrollment
29th of 33
24 · median 69
Started
2022
the only one that year
No phase
17 of 39
1 open now
Registered
35th of 39
by date

Among the 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich, this one is the 29th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2022, is one of 17 with no phase, and was the 35th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich, or all of them as a file.
02

Study summary

The investigators hypothesize that BFR exercise regimens result in a different acute cardiorespiratory response pattern compared to traditional exercise regimens. Furthermore, the investigators hypothesize that these patterns differ between healthy participants and participants with COPD.

Regarding secondary objective, the investigators hypothesize that BFR results in lower blood pressure responses compared to traditional exercise training in both healthy and COPD participants.

Read the detailed description

Detailed Description

This study investigates the acute physiological and perceptual responses to blood flow restriction (BFR) exercise compared with conventional endurance and resistance exercise in both patients with chronic obstructive pulmonary disease (COPD) and healthy individuals. The study consists of multiple experimental arms using randomized crossover designs to enable within-subject comparisons across exercise modalities and conditions.

Endurance Exercise - COPD Participants (Exhaustive Protocol)

Patients with COPD will complete three cycling exercise conditions in a randomized, crossover design:

Blood Flow Restriction Cycling (BFR-CYC)

Continuous Cycling (CONT-CYC)

Interval Cycling (INT-CYC)

All sessions will be performed on a cycle ergometer under standardized laboratory conditions, including a warm-up followed by the respective protocol. Exercise will be performed to symptom limitation (volitional exhaustion) unless predefined safety criteria are reached.

BFR-CYC: Continuous cycling at 50% peak work rate (PWR) with bilateral thigh cuffs inflated to 50% limb occlusion pressure (LOP). A maximum duration of 30 minutes is applied as a safety limit.

CONT-CYC: Continuous cycling at 65% PWR until symptom limitation.

INT-CYC: Interval cycling with repeated bouts at 80% PWR, interspersed with recovery periods at 50% PWR, until symptom limitation.

During all sessions, cardiorespiratory parameters (ventilation, oxygen uptake, carbon dioxide production), muscle oxygenation (NIRS), blood lactate, hemodynamic responses, and perceptual responses (dyspnea, perceived exertion) will be continuously measured.

Endurance Exercise - COPD and Healthy Participants (Fixed-Duration Protocol)

Both COPD patients and healthy participants will complete two endurance exercise conditions in a randomized, crossover design:

Blood Flow Restriction Cycling (BFR-CYC)

Non-BFR Control Cycling

All sessions will be conducted under standardized laboratory conditions on a cycle ergometer. Exercise will follow a fixed-duration protocol and will not be performed to volitional exhaustion, unless predefined safety criteria require early termination.

BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals.

Control: Time- and structure-matched protocol (3 × 2 minutes) without blood flow restriction at 65% PWR, with identical recovery periods.

During all sessions, cardiorespiratory, hemodynamic, and perceptual responses (dyspnea, perceived exertion) will be continuously measured.

Resistance Exercise - COPD and Healthy Participants (BFR vs Control, Fixed Protocol)

Both COPD patients and healthy participants will complete two resistance exercise conditions in a randomized, crossover design:

Blood Flow Restriction Resistance Exercise (BFR-RE)

Non-BFR Control Resistance Exercise

All sessions will be performed on a leg press device under standardized laboratory conditions. Exercise will follow a fixed set and repetition scheme and will not be performed to volitional exhaustion, unless predefined safety criteria require early termination.

BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions).

Control: Bilateral leg press at 40% 1RM, 3 sets of 15 repetitions, without blood flow restriction.

During all sessions, cardiorespiratory, hemodynamic, and perceptual responses will be continuously measured.

Resistance Exercise - Healthy Participants (LOP Comparison Arm)

Healthy participants will complete two BFR resistance exercise conditions in a randomized, crossover design:

BFR at 40% LOP

BFR at 80% LOP

All sessions will be conducted on a leg press device under standardized laboratory conditions. Pneumatic cuffs will be applied to the proximal thigh of the right leg.

Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.

Neuromuscular function will be assessed using maximal voluntary contraction (MVC) of the knee extensors measured before and immediately after exercise. Voluntary activation will be evaluated using the twitch interpolation technique with supramaximal electrical stimulation.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion and exclusion for the healthy participants are defined by the following criteria.

Inclusion criteria:

  • Age ≥ 18 years
  • Clinically healthy

Exclusion criteria:

  • Physical or intellectual impairment precluding or protocol adherence
  • Non-German speaking (precluding informed consent)
  • Pain during exercise of any origin
  • Pregnancy
  • History of thromboembolic event in the lower extremity
  • Resting systolic blood pressure \<100 mmHg

Inclusion and exclusion for the participants are defined by the following criteria.

Inclusion criteria:

  • Age ≥ 18 years
  • Diagnosed COPD according to GOLD-guidelines12

Exclusion criteria:

  • Physical or intellectual impairment precluding informed consent or protocol adherence
  • Non-German speaking (precluding informed consent)
  • Acute or recent (within the last 6 weeks) exacerbation of COPD
  • Pain during exercise of any origin
  • Pregnancy
  • History of thromboembolic event in the lower extremity
  • Resting systolic blood pressure \<100 mmHg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Endurance Exercise - COPD and Healthy Participants (Fixed-Duration Protocol)

    Both COPD patients and healthy participants will complete two endurance exercise conditions in a randomized, crossover design: * Blood Flow Restriction Cycling (BFR-CYC) * Non-BFR Control Cycling BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals. Control: Time- and structure-matched protocol (3 × 2 minutes) without blood flow restriction at 65% PWR, with identical recovery periods.

    Other: BFR-CYC 3x2min

  • Experimental
    Resistance Exercise - COPD and Healthy Participants (BFR vs Control, Fixed Protocol)

    Both COPD patients and healthy participants will complete two resistance exercise conditions in a randomized, crossover design: * Blood Flow Restriction Resistance Exercise (BFR-RE) * Non-BFR Control Resistance Exercise BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions). Control: Bilateral leg press at 40% 1RM, 3 sets of 15 repetitions, without blood flow restriction.

    Other: BFR Resistance 80% LOP

  • Experimental
    Endurance Exercise - COPD Participants (Exhaustive Protocol)

    Patients with COPD will complete three cycling exercise conditions in a randomized, crossover design: * Blood Flow Restriction Cycling (BFR-CYC) * Continuous Cycling (CONT-CYC) * Interval Cycling (INT-CYC)

    Other: BFR-CYC 50% peak / 50% AOP (exhaustive)

  • Experimental
    Resistance Exercise - Healthy Participants (LOP Comparison Arm)

    Healthy participants will complete two BFR resistance exercise conditions in a randomized, crossover design: * BFR at 40% LOP * BFR at 80% LOP Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.

    Other: BFR REsistance 48% vs. 80% LOP

Interventions

  • OtherBFR-CYC 50% peak / 50% AOP (exhaustive)

    BFR-CYC: Continuous cycling at 50% peak work rate (PWR) with bilateral thigh cuffs inflated to 50% limb occlusion pressure (LOP). A maximum duration of 30 minutes is applied as a safety limit.

  • OtherBFR-CYC 3x2min

    BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals.

  • OtherBFR Resistance 80% LOP

    BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions).

  • OtherBFR REsistance 48% vs. 80% LOP

    * BFR at 40% LOP * BFR at 80% LOP All sessions will be conducted on a leg press device under standardized laboratory conditions. Pneumatic cuffs will be applied to the proximal thigh of the right leg. Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.

06

What researchers measure

Primary outcomes

  1. Endurance Exercise:(Fixed-Duration Protocol):

    Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

  2. Resistance Exercise - Healthy Participants (LOP Comparison Arm): Within-subject difference change in Maximal Voluntary Contraction (MVC)

    Maximal voluntary contraction (MVC) of the knee extensors will be assessed before and immediately after unilateral leg press exercise performed with blood flow restriction at 40% and 80% limb occlusion pressure (LOP). MVC will be measured using an isometric setup, and voluntary activation will be evaluated using the twitch interpolation technique with supramaximal electrical stimulation. The primary outcome is the change in MVC from pre- to post-exercise, reflecting exercise-induced neuromuscular fatigue.

    Time frame: Pre-exercise and immediately post-exercise (within minutes after completion of the exercise protocol)

  3. Endurance Exercise - COPD Participants (Exhaustive Protocol): Within-subject difference in maximal minute ventilation (VE) between BFR and traditional exercise regimens

    Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand and response.

    Time frame: Continuously during exercise, at end of exercise (peak value), and within 4 minutes post-exercise

  4. Resistance Exercise:(Healthy and COPD): Ventilatory Response (Ventilation, VE)

    Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

Secondary outcomes

  1. Resistance Exercise - Healthy Participants (LOP Comparison Arm): Muscle Oxygenation (NIRS)

    Muscle oxygenation of the knee extensors will be continuously assessed using near-infrared spectroscopy (NIRS) during unilateral leg press exercise performed with blood flow restriction at 40% and 80% limb occlusion pressure (LOP). Parameters such as tissue oxygen saturation will be analyzed to evaluate local muscular oxygenation responses.

    Time frame: Continuously during exercise and immediately post-exercise

  2. Resistance Exercise - Healthy Participants (LOP Comparison Arm): Perceived Exertion / Dyspnea (Borg Scale)

    Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.

    Time frame: At baseline (pre-exercise), after each set, immediately post-exercise, and at 2 and 4 minutes post-exercise

  3. Endurance Exercise - COPD Participants (Exhaustive Protocol): Cardiorespiratory Response (Vo2 , VCO2)

    Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under three conditions (BFR-CYC, CONT-CYC, INT-CYC) to symptom limitation. The primary outcome will be the peak VO₂ achieved at end of exercise, reflecting maximal cardiorespiratory response. Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

  4. Endurance Exercise - COPD Participants (Exhaustive Protocol):NIRS

    Muscle oxygenation will be assessed using near-infrared spectroscopy (NIRS) during cycling exercise to evaluate local muscular oxygenation under BFR and non-BFR conditions.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

  5. Endurance Exercise - COPD Participants (Exhaustive Protocol): Blood Lactate Concentration

    Capillary blood lactate concentration will be measured to assess metabolic stress induced by the different exercise conditions.

    Time frame: At baseline (pre-exercise) at peak and 3 min wpost-exercise

  6. Endurance Exercise - COPD Participants (Exhaustive Protocol): Perceived Exertion and Dyspnea (Borg Scale)

    Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.

    Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise

  7. Endurance Exercise - COPD Participants (Exhaustive Protocol): Exercise Tolerance (Time to Exhaustion)

    Exercise tolerance will be defined as the time from the start of exercise to symptom limitation (volitional exhaustion).

    Time frame: During exercise (recorded at end of exercise)

  8. Endurance Exercise:(Fixed-Duration Protocol): Cardiorespiratory Response (Vo2 , VCO2)

    Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under two conditions. The primary outcome will be the peak VO₂ achieved at end of exercise, reflecting maximal cardiorespiratory response.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

  9. Endurance Exercise:(Fixed-Duration Protocol): Borg Scale (Dyspnea/Perceived Exertion)

    Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.

    Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise

  10. Resistance Exercise:(Healthy and COPD): Cardiorespiratory Response

    Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under two conditions. Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses.

    Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise

  11. Resistance Exercise:(Healthy and COPD): Dyspnea (Borg Scale/ Perceived Exertion )

    Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.

    Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kuhn M, Clarenbach CF, Klay A, Kohler M, Mayer LC, Luchinger M, Andrist B, Radtke T, Haile SR, Sievi NA, Kohlbrenner D. Exploring immediate cardiorespiratory responses: low-intensity blood flow restricted cycling vs. moderate-intensity traditional exercise in a randomized crossover trial. BMC Sports Sci Med Rehabil. 2024 Aug 15;16(1):172. doi: 10.1186/s13102-024-00951-0. PubMed 39148127 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 55 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Dec 20, 2021
StartActual
May 20, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163600
Responsible party
Christian Clarenbach (PD Dr. med Head of Pneumology, University of Zurich) — Principal investigator
First posted
Dec 20, 2021
Start date
May 20, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Christan Clarenbach, Dr. med
Contact
Christian.clarenbach@usz.ch
044 255 22 21
Manuel Kuhn, PhD Student
Contact
manuel.kuhn@usz.ch
0798526722
Christian Clarenbach, Dr. med
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion